{"nctId":"NCT01351480","briefTitle":"Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients","startDateStruct":{"date":"2011-06","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":34,"armGroups":[{"label":"abatacept","type":"OTHER","interventionNames":["Biological: abatacept"]}],"interventions":[{"name":"abatacept","otherNames":["orencia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able and willing to give written informed consent\n* Patients must have a diagnosis of rheumatoid arthritis \\> 3 months\n* Patients must have been receiving methotrexate for 12 weeks prior to screening at a dose of 10mg - 25 mg weekly.\n* Patient must have had an inadequate response after receiving or previously receiving one (1) but no more than two (2) anti-TNF biologic agents\n* Age \\>/= 18 yrs\n* Must have active RA as defined by a DAS28 (Erythrocyte sedimentation rate) score \\>4.4\n* Must have synovitis of at least two joints in one hand/wrist at screening and baseline\n* Must have a negative Pregnancy test and use adequate method of contraception throughout the trial\n* Stable use of Corticosteroids is permitted\n* Stable use of Non-steroidal anti-inflammatory drugs is permitted\n\nExclusion Criteria:\n\n* Functional Class IV\n* Pregnancy or breastfeeding\n* History of any other inflammatory arthritis\n* Sexually active patients who are not using acceptable birth control\n* Subjects who have undergone metacarpophalangeal (MCP) arthroplasty or anticipate the need for such a procedure\n* Subjects with a history of cancer in the last five years other than non melanoma skin cancers\n* Subjects who are unable to comply with study and followup procedures\n* Subjects who have current or severe symptoms of renal, hepatic, hematologic, gastrointestinal, pulmonary cardiac, neurologic, or cerebral disease\n* Subjects who currently abuse drugs or alcohol\n* Subjects with evidence of active or latent bacterial or viral infections at the time of enrollment\n* Subjects who have received live vaccines within 4 months of first dose of study medication\n* Subjects with herpes zoster or cytomegalovirus that resolved less than two months prior to dosing\n* Subjects at risk for tuberculosis (TB). Specifically excluded will be subjects with a history of active TB within the last 3 years and subjects with latent TB must have a negative chest X-ray and be started on treatment for at least 28 days prior to dosing.\n* Prior treatment with Rituximab within 12 months\n* Prior treatment with more than 2 TNFs\n* Intramuscular(IM), Intravenous(IV) Intra-articular (IA) corticosteroids within 28 days prior to baseline\n* Subjects who have a metal device affected by MRI (e.g. any type of electronic, mechanical or magnetic implant, metal slivers, metal objects, cardioverter defibrillator)\n* Subjects who have received any disease modifying agent (DMARD) other than methotrexate within the past 28 days prior to baseline","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With an Improvement in Bone Edema/Osteitis on Low-field MRI in Rheumatoid Arthritis Patients on Weekly SC Abatacept in Combination With Methotrexate Over a 12-month Period.","description":"bone edema/osteitis using low-field MRI analysis of 25 anatomical locations in the wrist and hand and scoring the volume of the original articular bone in 0.5 increments from 0-3, with each increment in the scale representing 33% of the volume of the peripheral 1 cm of original (eroded + residual) articular bone.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With an Improvement in DAS Score Were Considered Responders at Week 48","description":"Patient with a positive change in DAS score were considered responders . The DAS score is calculated using the number of tender and swollen joints based upon a 28 joint count, the ESR in mm/hr., and the physician global score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"To Measure the Change From Baseline in Patient DAS 28 Scores at Baseline and Weeks 12, 24","description":"DAS 28\\> 5.1=high disease activity DAS28 \\<3.2=low disease activity DAS28 \\<2.6=remission Criteria used in formula are number of tender joints based upon 28 joints, number of swollen joints based on 28 joints, ESR in mm/hr and patient global health core based on 0-10 mm","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"the Clinical Outcomes Measurements (American College of Rheumatology Activity Scoring, Health Assessment The Number of Patients With a Clinical Response at Week 24 and 48","description":"Patient with a positive change in DAS score were considered responders . The DAS score is calculated using the number of tender and swollen joints based upon a 28 joint count, the ESR in mm/hr., and the physician global score (1-10 cm). Total maximum score was at high disease activity at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events","description":"site will report the number of patients with adverse envents from Day 1 up to 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":[]}}}